A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT ID: NCT02376049
Last Updated: 2025-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2015-02-28
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT02496546
Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
NCT03091426
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
NCT03250624
Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
NCT00871208
A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis
NCT02103725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pimecrolimus cream
Pimecrolimus 1% cream once daily for 14 days
Pimecrolimus cream
Betamethasone dipropionate cream
Betamethasone dipropionate 0.05% cream once daily for 14 days
Betamethasone dipropionate cream
Clobetasol propionate cream
Clobetasol propionate 0.05% cream once daily for 14 days
Clobetasol propionate cream
Glaxal Base cream vehicle
Glaxal Base cream vehicle once daily for 14 days
Glaxal Base cream vehicle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pimecrolimus cream
Betamethasone dipropionate cream
Clobetasol propionate cream
Glaxal Base cream vehicle
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Four comparable TAs
* TSS of at least 5 on all TAs
* Difference in TSS not greater than 2 between the TAs
* Sign score erythema ≥ 2 between the TAs
* TAs should be at least 2 cm apart
Exclusion Criteria
* Fitzpatrick skin type \>5
* Topical (i.e. on the TAs) treatment with prohibited medications
* Systemic treatment with prohibited medications
* Phototherapy within prohibited timeframe
* Use of emollients within prohibited timeframe
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emma Guttmann, MD
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innovaderm Research Inc.
Montreal, Quebec, Canada
Beit Harofim
Netanya, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at LEO Pharma
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EXP-1184
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.